Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668417 · ClinicalTrials.gov registry record · NA
Pediatric Second Influenza Dose Portal Reminder Recall
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 698
- Enrollment target
NCT04668417: Completed NA study, sponsored by University of California, Los Angeles.
NCT04668417 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 698 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04668417, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 698 participants
- Enrollment target
Study Summary
This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System. The study design is a parallel 2-arm trial. The parallel arms are 1) a reminder letter for the second dose of influenza vaccine (reminder messages sent via the patient portal) with a direct appointment scheduling link included in the reminder and 2) a reminder letter for the second dose of influenza vaccine, but no direct appointment scheduling link included.
Primary Outcome
Receipt of a second dose of influenza vaccine (between 12/15/2020 and 4/1/21) among patients. Outcomes will be assessed via vaccine data extraction from the electronic health record and external claims and pharmacy data. The patient must also be an active UCLA Health MyChart user (\>= 1 login over the last 12 months from 12/15/2020), excluding activity on the user's initial profile activation date. Individuals not affiliated with any primary care practice will be excluded from the analysis.
Interventions
- BEHAVIORAL Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link
- BEHAVIORAL Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 698 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2021-04-01 |
| Phase | NA |
What the finished NCT04668417 record still lists
NCT04668417 is an interventional study that assigns participants to a tested intervention. The registered 698 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link is the first listed.
NCT04668417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04668417 about?
NCT04668417 is a clinical study titled "Pediatric Second Influenza Dose Portal Reminder Recall". This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System. The study design is a parallel 2-arm trial. The parallel arms are 1) a reminder letter for the second dose of influenza vaccine (reminder messages sent via the patient portal) wit...
What is the current status of trial NCT04668417?
This trial is currently completed. It is a NA study. The enrollment target is 698 participants. The study started on 2020-12-15. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04668417?
The interventions under investigation include: Portal Reminders for Second Dose of Influenza Vaccine with Direct Scheduling Link (BEHAVIORAL), Portal Reminders for Second Dose of Influenza Vaccine without Direct Scheduling Link (BEHAVIORAL).
Who is sponsoring clinical trial NCT04668417?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04668417's enrollment target sits among peer trials
698 151st of 2000 higher than 1,850 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03136094 · 698 participants · NA
Suicide in Urban Natives: Detection and Networks to Combat Events
- NCT04928846 · 698 participants · Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- NCT05943535 · 698 participants · Phase 3
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- NCT07187115 · 699 participants · NA
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI